English

MIRAGEN THERAPEUTICS, INC.

EDGAR

MGEN Quarterly report (10-Q) · filed 2026-08-06

71 filing records in this dataset, filed from 2014-03-19 to 2026-08-06. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

4.78 million USD

2018 Q1 · USD

Exact inputs and evidence

Revenue: 4784000 USD Source

Operating margin

-96.55%

2018 Q1 · %

Exact inputs and evidence

Operating Income: -4619000 USD Source
Revenue: 4784000 USD Source

Operating cash flow

-7.36 million USD

2018 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: -7361000 USD Source

Free cash flow

-7.46 million USD

2018 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: -7361000 USD Source
Capital Expenditure: 95000 USD Source

Cash and cash equivalents: 24.9 million USD 2019-09-30 Source
Exact value

24857000 USD
Long-term debt including current maturities: 20.3 million USD 2024-03-31 Source
Exact value

20328000 USD
Shares outstanding: 113 million shares 2026-06-30 Source
Exact value

113238218 shares

Reported share-count change

38.69% · 31.6 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

81651186 shares · 2025-06-30· Source
113238218 shares · 2026-06-30· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-06.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2017-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 10 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 11 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2018-12-31
Long-term debt including current maturities: 6 of 11 periods available· newest 2023-12-31
Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 72.65 million

Prior period

−USD 269.95 million

2024-01-01 – 2024-12-31
Current period

−USD 342.6 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-342601000 − -269949000 = -72652000 USD

-269949000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-342601000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · MIRAGEN THERAPEUTICS, INC. · 2025-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Year-over-year change in Net income: -72652000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -342601000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm#1525605 Filing: 000159075026000007 Input fundies:NetIncome: -269949000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm#1526377 Filing: 000159075026000007
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 44.07 million

Prior period

−USD 232.32 million

2024-01-01 – 2024-12-31
Current period

−USD 276.39 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-276391000 − -232319000 = -44072000 USD

-232319000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-276391000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · MIRAGEN THERAPEUTICS, INC. · 2025-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Year-over-year change in Operating cash flow: -44072000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -276391000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm#1552075 Filing: 000159075026000007 Input fundies:OperatingCashFlow: -232319000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm#1552730 Filing: 000159075026000007
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-3.1%

Prior period

USD 511,000

2024-01-01 – 2024-12-31
Current period

USD 495,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

495000 − 511000 = -16000 USD

511000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
495000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · MIRAGEN THERAPEUTICS, INC. · 2025-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Year-over-year change in Capital expenditure: -16000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 495000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm#1559186 Filing: 000159075026000007 Input fundies:CapitalExpenditure: 511000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm#1559744 Filing: 000159075026000007
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2017 2017-01-01 – 2017-12-31

Revenue USD 4 million 100% of revenue
Operating costs Derived USD 30.54 million 763% of revenue
Operating income −USD 26.53 million −663% of revenue
Tax, interest and other Derived −USD 20,000 −0.5% of revenue
Net income −USD 26.51 million −662% of revenue

Cash

Operating cash flow −USD 28.17 million −704% of revenue
Capital expenditure USD 246,000 6.1% of revenue
Free cash flow Derived −USD 28.41 million −710% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 589% of revenue.
2017 Operating loss: operating costs were 763% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	3477000	20464000 Derived	-16987000	287000 Derived	-17274000	-15005000 Derived	Source 2016-01-01 – 2016-12-31: 3477000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -16987000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -17274000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -14755000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 250000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	4003000	30535000 Derived	-26532000	-20000 Derived	-26512000	-28413000 Derived	Source 2017-01-01 – 2017-12-31: 4003000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -26532000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -26512000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -28167000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 246000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 4M 2017

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Revenue	2538000	Revenue: 2538000 Open source
20162016-12-31	Revenue	3477000	Revenue: 3477000 Open source
20172017-12-31	Revenue	4003000	Revenue: 4003000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

15.1% 2017

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Year over year	No prior comparable period	Revenue: 2538000 Open source
20162016-12-31	Year over year	37%	Revenue: 3477000 Open source Revenue: 2538000 Open source
20172017-12-31	Year over year	15.1%	Revenue: 4003000 Open source Revenue: 3477000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -662.8% 2017

Net margin -662.3% 2017

Free cash flow margin -709.8% 2017

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Operating margin	-440.8%	Operating Income: -11187000 Open source Revenue: 2538000 Open source
20162016-12-31	Operating margin	-488.6%	Operating Income: -16987000 Open source Revenue: 3477000 Open source
20172017-12-31	Operating margin	-662.8%	Operating Income: -26532000 Open source Revenue: 4003000 Open source
20152015-12-31	Net margin	-446.3%	Net Income: -11328000 Open source Revenue: 2538000 Open source
20162016-12-31	Net margin	-496.8%	Net Income: -17274000 Open source Revenue: 3477000 Open source
20172017-12-31	Net margin	-662.3%	Net Income: -26512000 Open source Revenue: 4003000 Open source
20152015-12-31	Free cash flow margin	Not reported	Revenue: 2538000 Open source
20162016-12-31	Free cash flow margin	-431.6%	Revenue: 3477000 Open source Operating Cash Flow: -14755000 Open source Capital Expenditure: 250000 Open source
20172017-12-31	Free cash flow margin	-709.8%	Revenue: 4003000 Open source Operating Cash Flow: -28167000 Open source Capital Expenditure: 246000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -28.2M 2017

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Operating cash flow	Not reported	No source recorded
20162016-12-31	Operating cash flow	-14755000	Operating Cash Flow: -14755000 Open source
20172017-12-31	Operating cash flow	-28167000	Operating Cash Flow: -28167000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -28.4M 2017

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20152015-12-31	Free cash flow	Unavailable	No source recorded
20162016-12-31	Free cash flow	-15005000	Operating Cash Flow: -14755000 Open source Capital Expenditure: 250000 Open source
20172017-12-31	Free cash flow	-28413000	Operating Cash Flow: -28167000 Open source Capital Expenditure: 246000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

26.6% 2017

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2015-12-31	Liabilities / assets	Not reported	Total Assets: 12902000 Open source
20162016-12-31	Liabilities / assets	39.2%	Total Liabilities: 9705000 Open source Total Assets: 24760000 Open source
20172017-12-31	Liabilities / assets	26.6%	Total Liabilities: 13971000 Open source Total Assets: 52481000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

13.31× 2017

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20152015-12-31	Current assets / current liabilities	4.75×	Current Assets: 11734000 Open source Current Liabilities: 2468000 Open source
20162016-12-31	Current assets / current liabilities	3.47×	Current Assets: 23877000 Open source Current Liabilities: 6885000 Open source
20172017-12-31	Current assets / current liabilities	13.31×	Current Assets: 51868000 Open source Current Liabilities: 3897000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 17.27 million Exact value Exact value: -17274000 USD 2016-01-01 – 2016-12-31: -17274000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MIRAGEN THERAPEUTICS, INC. · 2016-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Net Income: -17274000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -17274000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075018000006/mgen-20171231.xml#189550 Filing: 000159075018000006 The citation records this snapshot. The page link may show a newer release later.	−USD 14.76 million Exact value Exact value: -14755000 USD 2016-01-01 – 2016-12-31: -14755000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MIRAGEN THERAPEUTICS, INC. · 2016-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Operating Cash Flow: -14755000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14755000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075018000006/mgen-20171231.xml#188514 Filing: 000159075018000006 The citation records this snapshot. The page link may show a newer release later.	USD 250,000 Exact value Exact value: 250000 USD 2016-01-01 – 2016-12-31: 250000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MIRAGEN THERAPEUTICS, INC. · 2016-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Capital Expenditure: 250000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 250000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075018000006/mgen-20171231.xml#201432 Filing: 000159075018000006 The citation records this snapshot. The page link may show a newer release later.	−USD 15.01 million Calculation and evidence -14755000 − 250000 USD Exact free cash flow: -15005000 USD 2016-01-01 – 2016-12-31: -14755000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 250000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MIRAGEN THERAPEUTICS, INC. · 2016-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Free cash flow: -15005000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14755000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075018000006/mgen-20171231.xml#188514 Filing: 000159075018000006 Input fundies:CapitalExpenditure: 250000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075018000006/mgen-20171231.xml#201432 Filing: 000159075018000006 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 26.51 million Exact value Exact value: -26512000 USD 2017-01-01 – 2017-12-31: -26512000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MIRAGEN THERAPEUTICS, INC. · 2017-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Net Income: -26512000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -26512000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075019000013/mgen-20181231.xml#187293 Filing: 000159075019000013 The citation records this snapshot. The page link may show a newer release later.	−USD 28.17 million Exact value Exact value: -28167000 USD 2017-01-01 – 2017-12-31: -28167000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MIRAGEN THERAPEUTICS, INC. · 2017-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Operating Cash Flow: -28167000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -28167000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075019000013/mgen-20181231.xml#186257 Filing: 000159075019000013 The citation records this snapshot. The page link may show a newer release later.	USD 246,000 Exact value Exact value: 246000 USD 2017-01-01 – 2017-12-31: 246000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MIRAGEN THERAPEUTICS, INC. · 2017-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Capital Expenditure: 246000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 246000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075019000013/mgen-20181231.xml#199969 Filing: 000159075019000013 The citation records this snapshot. The page link may show a newer release later.	−USD 28.41 million Calculation and evidence -28167000 − 246000 USD Exact free cash flow: -28413000 USD 2017-01-01 – 2017-12-31: -28167000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 246000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MIRAGEN THERAPEUTICS, INC. · 2017-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Free cash flow: -28413000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -28167000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075019000013/mgen-20181231.xml#186257 Filing: 000159075019000013 Input fundies:CapitalExpenditure: 246000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075019000013/mgen-20181231.xml#199969 Filing: 000159075019000013 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 32.7 million Exact value Exact value: -32703000 USD 2018-01-01 – 2018-12-31: -32703000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MIRAGEN THERAPEUTICS, INC. · 2018-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Net Income: -32703000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -32703000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075020000021/mgen-20191231.xml#168481 Filing: 000159075020000021 The citation records this snapshot. The page link may show a newer release later.	−USD 26.84 million Exact value Exact value: -26844000 USD 2018-01-01 – 2018-12-31: -26844000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MIRAGEN THERAPEUTICS, INC. · 2018-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Operating Cash Flow: -26844000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -26844000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075020000021/mgen-20191231.xml#167444 Filing: 000159075020000021 The citation records this snapshot. The page link may show a newer release later.	USD 445,000 Exact value Exact value: 445000 USD 2018-01-01 – 2018-12-31: 445000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MIRAGEN THERAPEUTICS, INC. · 2018-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Capital Expenditure: 445000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 445000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075020000021/mgen-20191231.xml#179980 Filing: 000159075020000021 The citation records this snapshot. The page link may show a newer release later.	−USD 27.29 million Calculation and evidence -26844000 − 445000 USD Exact free cash flow: -27289000 USD 2018-01-01 – 2018-12-31: -26844000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 445000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MIRAGEN THERAPEUTICS, INC. · 2018-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Free cash flow: -27289000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -26844000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075020000021/mgen-20191231.xml#167444 Filing: 000159075020000021 Input fundies:CapitalExpenditure: 445000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075020000021/mgen-20191231.xml#179980 Filing: 000159075020000021 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 41.87 million Exact value Exact value: -41873000 USD 2019-01-01 – 2019-12-31: -41873000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MIRAGEN THERAPEUTICS, INC. · 2019-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Net Income: -41873000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -41873000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075021000029/mgen-20201231.htm#1207458 Filing: 000159075021000029 The citation records this snapshot. The page link may show a newer release later.	−USD 36.06 million Exact value Exact value: -36056000 USD 2019-01-01 – 2019-12-31: -36056000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MIRAGEN THERAPEUTICS, INC. · 2019-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Operating Cash Flow: -36056000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -36056000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075021000029/mgen-20201231.htm#1238333 Filing: 000159075021000029 The citation records this snapshot. The page link may show a newer release later.	USD 84,000 Exact value Exact value: 84000 USD 2019-01-01 – 2019-12-31: 84000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MIRAGEN THERAPEUTICS, INC. · 2019-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Capital Expenditure: 84000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 84000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075021000029/mgen-20201231.htm#1247641 Filing: 000159075021000029 The citation records this snapshot. The page link may show a newer release later.	−USD 36.14 million Calculation and evidence -36056000 − 84000 USD Exact free cash flow: -36140000 USD 2019-01-01 – 2019-12-31: -36056000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 84000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MIRAGEN THERAPEUTICS, INC. · 2019-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Free cash flow: -36140000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -36056000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075021000029/mgen-20201231.htm#1238333 Filing: 000159075021000029 Input fundies:CapitalExpenditure: 84000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075021000029/mgen-20201231.htm#1247641 Filing: 000159075021000029 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 110.72 million Exact value Exact value: -110715000 USD 2020-01-01 – 2020-12-31: -110715000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MIRAGEN THERAPEUTICS, INC. · 2020-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Net Income: -110715000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -110715000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075022000004/vrdn-20211231.htm#1224825 Filing: 000159075022000004 The citation records this snapshot. The page link may show a newer release later.	−USD 29.78 million Exact value Exact value: -29779000 USD 2020-01-01 – 2020-12-31: -29779000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MIRAGEN THERAPEUTICS, INC. · 2020-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Operating Cash Flow: -29779000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -29779000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075022000004/vrdn-20211231.htm#1262625 Filing: 000159075022000004 The citation records this snapshot. The page link may show a newer release later.	USD 42,000 Exact value Exact value: 42000 USD 2020-01-01 – 2020-12-31: 42000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MIRAGEN THERAPEUTICS, INC. · 2020-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Capital Expenditure: 42000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 42000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075022000004/vrdn-20211231.htm#1276420 Filing: 000159075022000004 The citation records this snapshot. The page link may show a newer release later.	−USD 29.82 million Calculation and evidence -29779000 − 42000 USD Exact free cash flow: -29821000 USD 2020-01-01 – 2020-12-31: -29779000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 42000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MIRAGEN THERAPEUTICS, INC. · 2020-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Free cash flow: -29821000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -29779000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075022000004/vrdn-20211231.htm#1262625 Filing: 000159075022000004 Input fundies:CapitalExpenditure: 42000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075022000004/vrdn-20211231.htm#1276420 Filing: 000159075022000004 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 79.41 million Exact value Exact value: -79413000 USD 2021-01-01 – 2021-12-31: -79413000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MIRAGEN THERAPEUTICS, INC. · 2021-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Net Income: -79413000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -79413000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075024000007/vrdn-20231231.htm#1307975 Filing: 000159075024000007 The citation records this snapshot. The page link may show a newer release later.	−USD 54.58 million Exact value Exact value: -54581000 USD 2021-01-01 – 2021-12-31: -54581000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MIRAGEN THERAPEUTICS, INC. · 2021-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Operating Cash Flow: -54581000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -54581000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075024000007/vrdn-20231231.htm#1342708 Filing: 000159075024000007 The citation records this snapshot. The page link may show a newer release later.	USD 338,000 Exact value Exact value: 338000 USD 2021-01-01 – 2021-12-31: 338000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MIRAGEN THERAPEUTICS, INC. · 2021-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Capital Expenditure: 338000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 338000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075024000007/vrdn-20231231.htm#1351471 Filing: 000159075024000007 The citation records this snapshot. The page link may show a newer release later.	−USD 54.92 million Calculation and evidence -54581000 − 338000 USD Exact free cash flow: -54919000 USD 2021-01-01 – 2021-12-31: -54581000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 338000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MIRAGEN THERAPEUTICS, INC. · 2021-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Free cash flow: -54919000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -54581000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075024000007/vrdn-20231231.htm#1342708 Filing: 000159075024000007 Input fundies:CapitalExpenditure: 338000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075024000007/vrdn-20231231.htm#1351471 Filing: 000159075024000007 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 129.87 million Exact value Exact value: -129874000 USD 2022-01-01 – 2022-12-31: -129874000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MIRAGEN THERAPEUTICS, INC. · 2022-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Net Income: -129874000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -129874000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075025000004/vrdn-20241231.htm#1441614 Filing: 000159075025000004 The citation records this snapshot. The page link may show a newer release later.	−USD 93.84 million Exact value Exact value: -93838000 USD 2022-01-01 – 2022-12-31: -93838000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MIRAGEN THERAPEUTICS, INC. · 2022-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Operating Cash Flow: -93838000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -93838000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075025000004/vrdn-20241231.htm#1474626 Filing: 000159075025000004 The citation records this snapshot. The page link may show a newer release later.	USD 797,000 Exact value Exact value: 797000 USD 2022-01-01 – 2022-12-31: 797000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MIRAGEN THERAPEUTICS, INC. · 2022-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Capital Expenditure: 797000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 797000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075025000004/vrdn-20241231.htm#1481636 Filing: 000159075025000004 The citation records this snapshot. The page link may show a newer release later.	−USD 94.64 million Calculation and evidence -93838000 − 797000 USD Exact free cash flow: -94635000 USD 2022-01-01 – 2022-12-31: -93838000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 797000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MIRAGEN THERAPEUTICS, INC. · 2022-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Free cash flow: -94635000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -93838000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075025000004/vrdn-20241231.htm#1474626 Filing: 000159075025000004 Input fundies:CapitalExpenditure: 797000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075025000004/vrdn-20241231.htm#1481636 Filing: 000159075025000004 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 237.73 million Exact value Exact value: -237734000 USD 2023-01-01 – 2023-12-31: -237734000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MIRAGEN THERAPEUTICS, INC. · 2023-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Net Income: -237734000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -237734000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm#1527150 Filing: 000159075026000007 The citation records this snapshot. The page link may show a newer release later.	−USD 184.17 million Exact value Exact value: -184170000 USD 2023-01-01 – 2023-12-31: -184170000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MIRAGEN THERAPEUTICS, INC. · 2023-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Operating Cash Flow: -184170000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -184170000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm#1553386 Filing: 000159075026000007 The citation records this snapshot. The page link may show a newer release later.	USD 898,000 Exact value Exact value: 898000 USD 2023-01-01 – 2023-12-31: 898000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MIRAGEN THERAPEUTICS, INC. · 2023-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Capital Expenditure: 898000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 898000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm#1560303 Filing: 000159075026000007 The citation records this snapshot. The page link may show a newer release later.	−USD 185.07 million Calculation and evidence -184170000 − 898000 USD Exact free cash flow: -185068000 USD 2023-01-01 – 2023-12-31: -184170000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 898000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MIRAGEN THERAPEUTICS, INC. · 2023-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Free cash flow: -185068000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -184170000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm#1553386 Filing: 000159075026000007 Input fundies:CapitalExpenditure: 898000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm#1560303 Filing: 000159075026000007 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 269.95 million Exact value Exact value: -269949000 USD 2024-01-01 – 2024-12-31: -269949000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MIRAGEN THERAPEUTICS, INC. · 2024-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Net Income: -269949000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -269949000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm#1526377 Filing: 000159075026000007 The citation records this snapshot. The page link may show a newer release later.	−USD 232.32 million Exact value Exact value: -232319000 USD 2024-01-01 – 2024-12-31: -232319000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MIRAGEN THERAPEUTICS, INC. · 2024-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Operating Cash Flow: -232319000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -232319000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm#1552730 Filing: 000159075026000007 The citation records this snapshot. The page link may show a newer release later.	USD 511,000 Exact value Exact value: 511000 USD 2024-01-01 – 2024-12-31: 511000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MIRAGEN THERAPEUTICS, INC. · 2024-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Capital Expenditure: 511000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 511000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm#1559744 Filing: 000159075026000007 The citation records this snapshot. The page link may show a newer release later.	−USD 232.83 million Calculation and evidence -232319000 − 511000 USD Exact free cash flow: -232830000 USD 2024-01-01 – 2024-12-31: -232319000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 511000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MIRAGEN THERAPEUTICS, INC. · 2024-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Free cash flow: -232830000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -232319000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm#1552730 Filing: 000159075026000007 Input fundies:CapitalExpenditure: 511000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm#1559744 Filing: 000159075026000007 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 342.6 million Exact value Exact value: -342601000 USD 2025-01-01 – 2025-12-31: -342601000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MIRAGEN THERAPEUTICS, INC. · 2025-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Net Income: -342601000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -342601000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm#1525605 Filing: 000159075026000007 The citation records this snapshot. The page link may show a newer release later.	−USD 276.39 million Exact value Exact value: -276391000 USD 2025-01-01 – 2025-12-31: -276391000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MIRAGEN THERAPEUTICS, INC. · 2025-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Operating Cash Flow: -276391000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -276391000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm#1552075 Filing: 000159075026000007 The citation records this snapshot. The page link may show a newer release later.	USD 495,000 Exact value Exact value: 495000 USD 2025-01-01 – 2025-12-31: 495000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MIRAGEN THERAPEUTICS, INC. · 2025-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Capital Expenditure: 495000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 495000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm#1559186 Filing: 000159075026000007 The citation records this snapshot. The page link may show a newer release later.	−USD 276.89 million Calculation and evidence -276391000 − 495000 USD Exact free cash flow: -276886000 USD 2025-01-01 – 2025-12-31: -276391000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 495000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MIRAGEN THERAPEUTICS, INC. · 2025-12-31 MIRAGEN THERAPEUTICS, INC. (edgar:1590750) Free cash flow: -276886000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1590750?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -276391000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm#1552075 Filing: 000159075026000007 Input fundies:CapitalExpenditure: 495000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/vrdn-20251231.htm#1559186 Filing: 000159075026000007 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

71 filings · 3,386 latest values · 3,386 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001590750, 1590750, MGEN, SGNL, VRDN, edgar:1590750, mgen, sgnl

Also known as MIRAGEN THERAPEUTICS, INC., Miragen Therapeutics, Inc., SIGNAL GENETICS LLC, SIGNAL GENETICS, INC., Viridian Therapeutics, Inc./DE, Viridian Therapeutics, Inc.\DE

MIRAGEN THERAPEUTICS, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2017 2017-01-01 – 2017-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation